Treatment-related adverse events ( AEs ) occurred in 44 % and 52 % , 57 % , and 41 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .
O O O O O O O O O O O O O O O O O O O O O O B-ChemicalEntity O O O O O O O B-ChemicalEntity O O O O O O O